Trial Profile
Phase I first-in-man trial of radiation enhancer MTL 005 in patients with advanced carcinoma of the head and neck
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2015
Price :
$35
*
At a glance
- Drugs MTL 005 (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Adverse reactions; First in man
- Sponsors MorEx Development Partners
- 27 Mar 2015 New trial record
- 11 Mar 2015 Part 1 of this trial has been completed and preliminary data have been reported at the 30th Conference on Clinical and Experimental Research in Radiation Oncology (CERRO), according to a MorEx media release.